Back to dashboard
All PlansCoverageLow impact

Transpupillary Thermotherapy for Treatment of Choroidal Neovascular Conditions

Blue Cross & Blue Shield of Mississippi·MS · Ophthalmology·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This policy confirms that Transpupillary Thermotherapy (TTT) for treating choroidal neovascular conditions remains investigational and non-covered. The policy scope was expanded in 2013 to include central serous chorioretinopathy and other choroidal conditions beyond just age-related macular degeneration.

Action Required

Action needed
No immediate action required. Continue to verify coverage for transpupillary thermotherapy procedures as this treatment remains investigational and will be denied by BCBS Mississippi. Inform providers that TTT is not covered for any choroidal neovascular conditions including AMD, central serous chorioretinopathy, and other related conditions.

Affected Billing Codes

67299

Related policy hubs